-

11:00:32 AM

ABBV Stock News

ABBV - Abbvie Inc

01/24/22 8:00 AM

NYSE : ABBV

Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)

Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX ® Cosmetic Story. The company continues its commitment to showcase real people and real

RHEA-AI

neutral

01/21/22 4:30 PM

NYSE : ABBV

fda approval

U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and

RHEA-AI

neutral

01/14/22 1:10 PM

NYSE : ABBV

fda approval

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not

RHEA-AI

neutral

01/11/22 8:45 AM

NYSE : ABBV

AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025

AbbVie (NYSE: ABBV) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion

RHEA-AI

neutral

01/11/22 7:45 AM

Nasdaq, NYSE : HZNP, ABBV, ABT

management

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie

RHEA-AI

very positive

01/07/22 9:00 AM

NYSE : ABBV

AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approvals for upadacitinib (RINVOQ ®, 15 mg once daily) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adults

RHEA-AI

neutral

01/05/22 8:00 AM

NYSE : ABBV

conferencesearnings

AbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2021 financial results on Wednesday, February 2, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible

RHEA-AI

neutral

01/04/22 8:15 AM

NYSE : ABBV

AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer

AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal

RHEA-AI

positive

01/04/22 8:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Members of AbbVie's executive leadership team will present virtually at 2:45 p.m. CT, including Robert A. Michael, vice

RHEA-AI

neutral

12/16/21 8:57 AM

NYSE, Nasdaq : ABBV, SOLY

acquisition

Allergan Aesthetics Completes Acquisition of Soliton

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY). The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

ABBV Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.abbvie.com
CeoRichard Gonzalez
Security nameAbbvie Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 N Waukegan Rd
StateIllinois
CityNorth Chicago
Zip60064-1802
CountryUS
Phone18479327900

ABBV Description:

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.